Case of sorafenib-induced thyroid storm

Journal of Clinical Oncology

Volumn 31, Issue 16, 2013, Pages

  Haraldsdottir, Sigurdis ^a   Li, Quan ^a   Villalona Calero, Miguel A ^a   Olencki, Thomas E ^a   Kendra, Kari ^a   Ing, Steven W ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DILTIAZEM; HYDROCORTISONE; PAZOPANIB; PROPRANOLOL; PROPYLTHIOURACIL; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; THYROGLOBULIN; THYROTROPIN; THYROXINE; ANTIARRHYTHMIC AGENT; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; THYROID HORMONE;

AGED; ANOREXIA; ARTICLE; CASE REPORT; CONFUSION; DIAPHORESIS; DIARRHEA; DRUG MEGADOSE; ECHOGRAPHY; FATIGUE; FREE THYROXINE INDEX; HEART ATRIUM FIBRILLATION; HUMAN; IMAGE ANALYSIS; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; SIDE EFFECT; THYROID CRISIS; THYROID FUNCTION TEST; TREMOR; ACID ASPIRATION; ADRENAL TUMOR; BLOOD; BONE TUMOR; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG ANTAGONISM; FATALITY; HEART ARREST; KIDNEY TUMOR; LUNG TUMOR; METASTASIS; MUSCLE TUMOR; PATHOLOGY;

ADRENAL GLAND NEOPLASMS; AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ANTINEOPLASTIC AGENTS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; BONE NEOPLASMS; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; FATAL OUTCOME; HEART ARREST; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MUSCLE NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RESPIRATORY ASPIRATION; THYROID CRISIS; THYROID HORMONES;

MLCS; MLOWN;

EID: 84880653613     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.7142     Document Type: Article

References (20)

1. Desai J, Yassa L, Marqusee E, et al: Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 145:660-664, 2006
2. Ellis LM, Hicklin DJ: VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer 8:579-591, 2008
3. Karaman MW, Herrgard S, Treiber DK, et al: A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127-132, 2008
4. Sternberg CN, Davis ID, Mardiak J, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 28:1061-1068, 2010
5. Brown RL: Tyrosine kinase inhibitor-induced hypothyroidism: Incidence, etiology, and management. Targeted Oncology 6:217-226, 2011
6. Schmidinger M, Vogl UM, Bojic M, et al: Hypothyroidism in patients with renal cell carcinoma: Blessing or curse? Cancer 117:534-544, 2011
7. Rini BI, Tamaskar I, Shaheen P, et al: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99:81-83, 2007
8. Miyake H, Kurahashi T, Yamanaka K, et al: Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: A prospective evaluation. Urol Oncol 28:515-519, 2010
9. Tamaskar I, Bukowski R, Elson P, et al: Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 19:265-268, 2008
10. Fujiwara Y, Kiyota N, Chayahara N, et al: Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: Results from phase I studies in Japanese patients. Invest New Drugs 30:1055-1064, 2012
11. Feldt S, Schüssel K, Quinzler R, et al: Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: A cohort study. Eur J Cancer 48:974-981, 2012
12. Naranjo CA, Busto U, Sellers EM, et al: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239-245, 1981
13. Kamba T, McDonald DM: Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788-1795, 2007
14. Wong E, Rosen LS, Mulay M, et al: Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 17:351-355, 2007
15. Mannavola D, Coco P, Vannucchi G, et al: A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 92:3531-3534, 2007
16. Barbaro D: Sorafenib and thyrotoxicosis. J Endocrinol Invest 33:436, 2010
17. van Doorn L, Eskens FA, Visser TJ, et al: Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. Thyroid 21:197-202, 2011
18. Grossmann M, Premaratne E, Desai J, et al: Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 69:669-672, 2008
19. Riesenbeck LM, Bierer S, Hoffmeister I, et al: Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J Urol 29:807-813, 2011
20. Wolter P, Stefan C, Decallonne B, et al: The clinical implications of sunitinib-induced hypothyroidism: A prospective evaluation. Br J Cancer 99:448-454, 2008